Frontiers in cellular and infection microbiology · 2026
Efficacy of a standardized cranberry supplement on overactive bladder symptoms and urobiome alterations in young women: a randomized, double-blind, placebo-controlled pilot trial.
СтатьяРандомизированное исследованиеКлиническое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ito Ayaka, Akagawa Shohei, Akagawa Yuko, Tsuji Shoji, Kato Shogo, Yamanouchi Sohsaku, Kaneko Kazunari
Аннотация
INTRODUCTION: Urobiome dysbiosis has been implicated in the pathogenesis of overactive bladder (OAB). In this study, the efficacy of a cranberry supplement for OAB symptoms was investigated, and concurrent urobiome alterations were evaluated in young women.
METHODS: This double-blind, randomized, placebo-controlled trial enrolled 26 women (median age, 23 years) with OAB (Overactive Bladder Symptom Score [OABSS] ≥ 3), who received either a cranberry supplement (36 mg proanthocyanidins per day) or placebo for 4 weeks. Clinical efficacy was assessed using the OABSS reduction rate, and urobiome composition was evaluated by 16S rRNA gene sequencing.
RESULTS: Twenty-five participants were included in the analysis. At 4 weeks, the OABSS reduction rate was greater in the cranberry group than in the placebo group (median, 66.7% vs. 40.0%; p = 0.039). At baseline, the urobiome was dominated by Lactobacillus (median relative abundance, 64.2%). After cranberry supplementation, the relative abundance of Lactobacillus decreased within the cranberry group (median change, -4.39%; p = 0.027; q = 0.096). No compositional changes were observed in the placebo group.
CONCLUSIONS: Cranberry supplementation was associated with greater improvement in OAB symptoms than was observed with placebo in young women, while a decrease in Lactobacillus relative abundance was observed within the cranberry group. Given the small sample size of this exploratory pilot trial and the limited species-level resolution of 16S rRNA sequencing, these concurrent findings should be regarded as hypothesis-generating and warrant further investigation.
CLINICAL TRIAL REGISTRATION: https://www.umin.ac.jp/ctr/, identifier UMIN000057544.
METHODS: This double-blind, randomized, placebo-controlled trial enrolled 26 women (median age, 23 years) with OAB (Overactive Bladder Symptom Score [OABSS] ≥ 3), who received either a cranberry supplement (36 mg proanthocyanidins per day) or placebo for 4 weeks. Clinical efficacy was assessed using the OABSS reduction rate, and urobiome composition was evaluated by 16S rRNA gene sequencing.
RESULTS: Twenty-five participants were included in the analysis. At 4 weeks, the OABSS reduction rate was greater in the cranberry group than in the placebo group (median, 66.7% vs. 40.0%; p = 0.039). At baseline, the urobiome was dominated by Lactobacillus (median relative abundance, 64.2%). After cranberry supplementation, the relative abundance of Lactobacillus decreased within the cranberry group (median change, -4.39%; p = 0.027; q = 0.096). No compositional changes were observed in the placebo group.
CONCLUSIONS: Cranberry supplementation was associated with greater improvement in OAB symptoms than was observed with placebo in young women, while a decrease in Lactobacillus relative abundance was observed within the cranberry group. Given the small sample size of this exploratory pilot trial and the limited species-level resolution of 16S rRNA sequencing, these concurrent findings should be regarded as hypothesis-generating and warrant further investigation.
CLINICAL TRIAL REGISTRATION: https://www.umin.ac.jp/ctr/, identifier UMIN000057544.